Project Details
| Short title | NN9838-4942 |
|---|---|
| Acronym | REDEFINE-3 |
| Status | Active |
| Effective start/end date | 31/07/23 → 28/06/28 |
CTU: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease
- Preda, Veronica (Primary Chief Investigator)
- Contacos, Christine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
Project: Research